Investors \u2014 Azuriya Pharma<\/title>\n<meta name=\"description\" content=\"Azuriya Pharma investor overview: $15B+ IBD market, multiple paths to liquidity, late-stage oral asset with composition of matter IP through 2044+.\">\n<link rel=\"icon\" href=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\">\n<style>\n\/* ============================================================\n Azuriya Pharma \u2014 Website Design System\n Derived from the Azuriya logo: indigo \/ emerald \/ violet gradient\n ============================================================ *\/\n\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Fraunces:ital,opsz,wght@0,9..144,300..900;1,9..144,300..900&family=Manrope:wght@300;400;500;600;700;800&family=JetBrains+Mono:wght@400;500;600&display=swap');\n\n:root {\n \/* === BRAND CORE (from logo) === *\/\n --indigo: #1C1691; \/* Primary \u2014 \"Azuriya\" wordmark *\/\n --indigo-deep: #14107A; \/* Hover \/ pressed *\/\n --ink: #0B0A4E; \/* Deep background for hero \/ footer *\/\n --emerald: #00A03C; \/* Secondary \u2014 green arc *\/\n --emerald-bright:#14BE54; \/* Hover highlight *\/\n --violet: #8B4FD8; \/* Accent \u2014 gradient start *\/\n --magenta: #C850DC; \/* Accent \u2014 gradient end *\/\n\n \/* === TINTS & SURFACES === *\/\n --cloud: #F7F8FC;\n --lavender: #F0EBFA;\n --mint: #E6F7EC;\n --white: #FFFFFF;\n\n \/* === TEXT === *\/\n --ink-body: #1A1A2E; \/* body text \u2014 indigo-tinted charcoal *\/\n --ink-muted: #555566;\n --ink-subtle: #8A8A9C;\n\n \/* === LINES === *\/\n --line: #E4E4F0;\n --line-strong: #C8C8DC;\n\n \/* === EFFECTS === *\/\n --gradient-accent: linear-gradient(90deg, var(--violet) 0%, var(--magenta) 100%);\n --gradient-brand: linear-gradient(135deg, var(--indigo) 0%, var(--violet) 100%);\n --gradient-hero: linear-gradient(135deg, #0B0A4E 0%, #1C1691 60%, #2E1E8C 100%);\n\n --shadow-sm: 0 1px 2px rgba(11,10,78,0.04), 0 1px 3px rgba(11,10,78,0.06);\n --shadow-md: 0 4px 12px rgba(11,10,78,0.06), 0 8px 24px rgba(11,10,78,0.04);\n --shadow-lg: 0 12px 32px rgba(11,10,78,0.08), 0 24px 64px rgba(11,10,78,0.06);\n\n \/* === RADII === *\/\n --r-sm: 4px;\n --r-md: 8px;\n --r-lg: 14px;\n --r-xl: 22px;\n\n \/* === TYPE SCALE === *\/\n --f-display: 'Fraunces', 'Georgia', serif;\n --f-sans: 'Manrope', -apple-system, BlinkMacSystemFont, sans-serif;\n --f-mono: 'JetBrains Mono', 'SF Mono', Menlo, monospace;\n}\n\n\/* ========== RESET ========== *\/\n*, *::before, *::after { box-sizing: border-box; }\nhtml { -webkit-text-size-adjust: 100%; scroll-behavior: smooth; }\nbody {\n margin: 0;\n font-family: var(--f-sans);\n font-size: 17px;\n line-height: 1.65;\n color: var(--ink-body);\n background: var(--white);\n font-feature-settings: 'ss01', 'cv11';\n -webkit-font-smoothing: antialiased;\n -moz-osx-font-smoothing: grayscale;\n}\n@media (min-width: 1600px) {\n body { font-size: 18px; }\n}\n@media (max-width: 640px) {\n body { font-size: 16px; line-height: 1.6; }\n}\nimg { max-width: 100%; display: block; }\na { color: var(--indigo); text-decoration: none; transition: color .15s ease; }\na:hover { color: var(--violet); }\nbutton { font-family: inherit; cursor: pointer; }\n\n\/* ========== TYPOGRAPHY ========== *\/\nh1, h2, h3, h4 {\n font-family: var(--f-display);\n font-weight: 500;\n line-height: 1.12;\n letter-spacing: -0.02em;\n color: var(--ink);\n margin: 0 0 .5em;\n font-variation-settings: 'opsz' 144;\n}\nh1 { font-size: clamp(2.6rem, 5.5vw, 5rem); line-height: 1.06; }\nh2 { font-size: clamp(2rem, 4vw, 3.2rem); line-height: 1.12; }\nh3 { font-size: clamp(1.4rem, 2.4vw, 1.75rem); font-family: var(--f-sans); font-weight: 700; letter-spacing: -0.01em; line-height: 1.25; }\nh4 { font-size: 1.15rem; font-family: var(--f-sans); font-weight: 600; letter-spacing: 0; }\n\n.eyebrow {\n font-family: var(--f-sans);\n font-size: .88rem;\n font-weight: 700;\n text-transform: uppercase;\n letter-spacing: .18em;\n color: var(--emerald);\n display: inline-flex;\n align-items: center;\n gap: .55rem;\n}\n.eyebrow::before {\n content: '';\n display: inline-block;\n width: 22px;\n height: 1px;\n background: var(--emerald);\n}\n\n.lead { font-size: clamp(1.15rem, 1.4vw, 1.4rem); line-height: 1.55; color: var(--ink-muted); max-width: 62ch; }\n.mono { font-family: var(--f-mono); font-size: .92em; letter-spacing: -.01em; }\n\n\/* Italic emphasis in serif headlines gets a violet tint *\/\nh1 em, h2 em, .serif em {\n font-style: italic;\n font-weight: 400;\n background: var(--gradient-accent);\n -webkit-background-clip: text;\n background-clip: text;\n -webkit-text-fill-color: transparent;\n}\n\n\/* ========== LAYOUT ========== *\/\n.wrap { max-width: 1320px; margin: 0 auto; padding: 0 32px; }\n.narrow { max-width: 960px; margin: 0 auto; padding: 0 32px; }\n.section { padding: clamp(4rem, 8vw, 8rem) 0; }\n.section-sm { padding: clamp(2.5rem, 5vw, 4.5rem) 0; }\n@media (max-width: 640px) {\n .wrap, .narrow { padding: 0 20px; }\n}\n\n\/* ========== NAV ========== *\/\n.nav {\n position: sticky; top: 0; z-index: 50;\n background: rgba(255,255,255,.88);\n backdrop-filter: saturate(180%) blur(12px);\n -webkit-backdrop-filter: saturate(180%) blur(12px);\n border-bottom: 1px solid var(--line);\n}\n.nav-inner {\n max-width: 1320px; margin: 0 auto;\n padding: 20px 32px;\n display: flex; align-items: center; justify-content: space-between;\n gap: 32px;\n}\n.nav-brand {\n display: flex; align-items: center; gap: 10px;\n text-decoration: none;\n}\n.nav-brand img { height: 44px; width: auto; }\n.nav-links {\n display: flex; gap: 32px; align-items: center;\n list-style: none; margin: 0; padding: 0;\n}\n.nav-links a {\n font-size: 1.02rem;\n font-weight: 500;\n color: var(--ink-body);\n position: relative;\n padding: 4px 0;\n}\n.nav-links a:hover { color: var(--indigo); }\n.nav-links a.is-active { color: var(--indigo); }\n.nav-links a.is-active::after {\n content: ''; position: absolute; left: 0; right: 0; bottom: -4px;\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n}\n.nav-cta {\n padding: 12px 22px;\n border-radius: 999px;\n background: var(--indigo);\n color: var(--white) !important;\n font-weight: 600;\n font-size: .98rem;\n transition: all .15s ease;\n}\n.nav-cta:hover { background: var(--indigo-deep); transform: translateY(-1px); }\n\n.nav-toggle { display: none; background: none; border: 0; padding: 6px; cursor: pointer; }\n.nav-toggle svg { width: 28px; height: 28px; color: var(--indigo); }\n\n\/* Mobile drawer: revealed when .nav has .is-open *\/\n.nav-mobile {\n display: none;\n border-top: 1px solid var(--line);\n background: var(--white);\n padding: 16px 32px 24px;\n}\n.nav-mobile ul { list-style: none; margin: 0; padding: 0; }\n.nav-mobile li { border-bottom: 1px solid var(--line); }\n.nav-mobile li:last-child { border-bottom: 0; }\n.nav-mobile a {\n display: block;\n padding: 16px 0;\n font-size: 1.12rem;\n font-weight: 500;\n color: var(--ink);\n}\n.nav-mobile a:hover, .nav-mobile a.is-active { color: var(--indigo); }\n.nav-mobile .nav-cta {\n display: inline-block;\n margin-top: 20px;\n color: var(--white) !important;\n}\n.nav.is-open .nav-mobile { display: block; }\n\n@media (max-width: 1024px) {\n .nav-links { display: none; }\n .nav-toggle { display: block; }\n .nav-inner > .nav-cta { display: none; } \/* Contact CTA moves into drawer *\/\n}\n@media (max-width: 640px) {\n .nav-inner { padding: 16px 20px; }\n .nav-brand img { height: 38px; }\n .nav-mobile { padding: 16px 20px 24px; }\n}\n\n\/* ========== BUTTONS ========== *\/\n.btn {\n display: inline-flex; align-items: center; gap: 8px;\n padding: 16px 28px;\n border-radius: 999px;\n font-weight: 600;\n font-size: 1rem;\n text-decoration: none;\n transition: all .18s ease;\n border: 0;\n}\n.btn-primary { background: var(--indigo); color: var(--white); }\n.btn-primary:hover { background: var(--indigo-deep); color: var(--white); transform: translateY(-1px); box-shadow: var(--shadow-md); }\n\n.btn-emerald { background: var(--emerald); color: var(--white); }\n.btn-emerald:hover { background: var(--emerald-bright); color: var(--white); transform: translateY(-1px); }\n\n.btn-ghost {\n background: transparent;\n color: var(--indigo);\n border: 1.5px solid var(--line-strong);\n}\n.btn-ghost:hover { border-color: var(--indigo); background: var(--lavender); color: var(--indigo); }\n\n.btn-light {\n background: rgba(255,255,255,0.1);\n color: var(--white);\n border: 1.5px solid rgba(255,255,255,0.25);\n backdrop-filter: blur(8px);\n}\n.btn-light:hover { background: rgba(255,255,255,0.18); color: var(--white); border-color: rgba(255,255,255,0.5); }\n\n\/* ========== HERO ========== *\/\n.hero {\n position: relative;\n background: var(--gradient-hero);\n color: var(--white);\n padding: clamp(5rem, 10vw, 8rem) 0 clamp(4rem, 8vw, 6rem);\n overflow: hidden;\n}\n.hero::before {\n \/* subtle molecular network texture *\/\n content: '';\n position: absolute; inset: 0;\n background-image:\n radial-gradient(circle at 20% 30%, rgba(139,79,216,0.18) 0%, transparent 40%),\n radial-gradient(circle at 80% 70%, rgba(0,160,60,0.12) 0%, transparent 45%),\n radial-gradient(circle at 50% 100%, rgba(200,80,220,0.10) 0%, transparent 50%);\n pointer-events: none;\n}\n.hero::after {\n content: '';\n position: absolute; inset: 0;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' width='160' height='160' viewBox='0 0 160 160'><g fill='none' stroke='white' stroke-opacity='0.05' stroke-width='1'><circle cx='80' cy='80' r='3'\/><circle cx='20' cy='40' r='2'\/><circle cx='140' cy='120' r='2'\/><circle cx='40' cy='130' r='2.5'\/><circle cx='120' cy='30' r='2.5'\/><path d='M80 80 L20 40 M80 80 L140 120 M80 80 L40 130 M80 80 L120 30'\/><\/g><\/svg>\");\n background-size: 320px 320px;\n opacity: .5;\n pointer-events: none;\n}\n.hero > .wrap { position: relative; z-index: 1; }\n.hero h1 { color: var(--white); }\n.hero .eyebrow { color: #6FE5A1; }\n.hero .eyebrow::before { background: #6FE5A1; }\n.hero .lead { color: rgba(255,255,255,.85); font-size: clamp(1.2rem, 1.5vw, 1.45rem); max-width: 58ch; }\n\n\/* ========== CARD \/ PANEL ========== *\/\n.card {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 28px;\n transition: all .2s ease;\n}\n.card:hover { border-color: var(--line-strong); box-shadow: var(--shadow-md); transform: translateY(-2px); }\n.card-tint-lav { background: var(--lavender); border-color: transparent; }\n.card-tint-mint { background: var(--mint); border-color: transparent; }\n\n\/* ========== STAT STRIP ========== *\/\n.stats {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));\n gap: 0;\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n overflow: hidden;\n background: var(--white);\n}\n.stat {\n padding: 40px 32px;\n border-right: 1px solid var(--line);\n position: relative;\n}\n.stat:last-child { border-right: 0; }\n.stat-value {\n font-family: var(--f-display);\n font-size: clamp(2.4rem, 4.5vw, 3.6rem);\n font-weight: 500;\n line-height: 1;\n color: var(--indigo);\n letter-spacing: -0.03em;\n margin-bottom: 10px;\n}\n.stat-label {\n font-size: .88rem;\n text-transform: uppercase;\n letter-spacing: .12em;\n color: var(--ink-muted);\n font-weight: 600;\n}\n.stat-note { font-size: .95rem; color: var(--ink-muted); margin-top: 6px; }\n@media (max-width: 720px) {\n .stat { padding: 28px 24px; border-right: 0; border-bottom: 1px solid var(--line); }\n .stat:last-child { border-bottom: 0; }\n}\n\n\/* ========== PILLAR GRID ========== *\/\n.pillars {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));\n gap: 24px;\n}\n.pillar {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 32px;\n position: relative;\n transition: all .2s ease;\n}\n.pillar:hover { border-color: var(--indigo); transform: translateY(-3px); box-shadow: var(--shadow-md); }\n.pillar-num {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n margin-bottom: 12px;\n letter-spacing: .02em;\n}\n.pillar-title {\n font-family: var(--f-display);\n font-size: clamp(1.4rem, 1.8vw, 1.65rem);\n font-weight: 500;\n letter-spacing: -0.015em;\n color: var(--ink);\n margin: 0 0 14px;\n line-height: 1.15;\n}\n.pillar-body { font-size: 1rem; color: var(--ink-muted); line-height: 1.6; }\n@media (max-width: 640px) {\n .pillars { grid-template-columns: 1fr; gap: 16px; }\n .pillar { padding: 24px; }\n}\n\n\/* ========== TABLE ========== *\/\n.tbl-wrap { overflow-x: auto; -webkit-overflow-scrolling: touch; margin: 0 -4px; padding: 0 4px; }\n.tbl {\n width: 100%;\n border-collapse: collapse;\n font-size: 1rem;\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-md);\n overflow: hidden;\n}\n.tbl th {\n text-align: left;\n padding: 16px 20px;\n background: var(--cloud);\n border-bottom: 1px solid var(--line);\n font-size: .82rem;\n text-transform: uppercase;\n letter-spacing: .1em;\n color: var(--ink-muted);\n font-weight: 700;\n}\n.tbl td {\n padding: 16px 20px;\n border-bottom: 1px solid var(--line);\n vertical-align: top;\n}\n.tbl tr:last-child td { border-bottom: 0; }\n.tbl tr:hover td { background: var(--cloud); }\n@media (max-width: 640px) {\n .tbl { font-size: .95rem; min-width: 560px; }\n .tbl th, .tbl td { padding: 12px 14px; }\n}\n\n\/* ========== BADGES & CHIPS ========== *\/\n.badge {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 4px 11px;\n font-size: .78rem;\n font-weight: 700;\n letter-spacing: .08em;\n text-transform: uppercase;\n border-radius: 4px;\n}\n.badge-new { background: var(--emerald); color: var(--white); }\n.badge-indigo { background: var(--lavender); color: var(--indigo); }\n.badge-violet { background: linear-gradient(90deg, rgba(139,79,216,.15), rgba(200,80,220,.15)); color: var(--violet); }\n.badge-outline{ background: transparent; color: var(--ink-muted); border: 1px solid var(--line-strong); }\n\n.chip {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 6px 14px;\n font-size: .88rem;\n font-weight: 500;\n border-radius: 999px;\n background: var(--cloud);\n border: 1px solid var(--line);\n color: var(--ink-body);\n}\n.chip.is-active { background: var(--indigo); color: var(--white); border-color: var(--indigo); }\n.chip:hover:not(.is-active) { background: var(--lavender); border-color: var(--violet); color: var(--indigo); cursor: pointer; }\n\n\/* ========== SECTION DIVIDER ========== *\/\n.divider {\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n width: 60px;\n margin: 0 0 24px;\n}\n\n\/* ========== FOOTER ========== *\/\n.foot {\n background: var(--ink);\n color: rgba(255,255,255,.78);\n padding: 72px 0 32px;\n margin-top: 72px;\n}\n.foot a { color: rgba(255,255,255,.78); }\n.foot a:hover { color: var(--white); }\n.foot-grid {\n display: grid;\n grid-template-columns: 2fr 1fr 1fr 1fr;\n gap: 56px;\n margin-bottom: 56px;\n}\n.foot h4 {\n color: var(--white);\n font-size: .85rem;\n text-transform: uppercase;\n letter-spacing: .15em;\n margin: 0 0 18px;\n font-weight: 700;\n}\n.foot ul { list-style: none; padding: 0; margin: 0; }\n.foot ul li { margin-bottom: 12px; font-size: 1rem; }\n.foot-brand img { height: 54px; margin-bottom: 20px; filter: brightness(0) invert(1) opacity(.88); }\n.foot-copy {\n padding-top: 32px;\n border-top: 1px solid rgba(255,255,255,.12);\n font-size: .9rem;\n display: flex;\n justify-content: space-between;\n flex-wrap: wrap;\n gap: 16px;\n}\n@media (max-width: 900px) {\n .foot-grid { grid-template-columns: 1fr 1fr; gap: 36px; }\n}\n@media (max-width: 520px) {\n .foot-grid { grid-template-columns: 1fr; gap: 32px; }\n .foot { padding: 56px 0 24px; }\n}\n\n\/* ========== UTILS ========== *\/\n.grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 56px; }\n.grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 28px; }\n.grid-4 { display: grid; grid-template-columns: repeat(4, 1fr); gap: 24px; }\n@media (max-width: 1024px) {\n .grid-4 { grid-template-columns: repeat(2, 1fr); }\n}\n@media (max-width: 800px) {\n .grid-2, .grid-3 { grid-template-columns: 1fr; gap: 32px; }\n}\n@media (max-width: 640px) {\n .grid-4 { grid-template-columns: 1fr; gap: 16px; }\n}\n\n.text-center { text-align: center; }\n.mt-1 { margin-top: 8px; } .mt-2 { margin-top: 16px; } .mt-3 { margin-top: 24px; } .mt-4 { margin-top: 40px; } .mt-5 { margin-top: 64px; }\n.mb-1 { margin-bottom: 8px; } .mb-2 { margin-bottom: 16px; } .mb-3 { margin-bottom: 24px; } .mb-4 { margin-bottom: 40px; }\n\n\/* Tint backgrounds for sections *\/\n.bg-cloud { background: var(--cloud); }\n.bg-lavender { background: var(--lavender); }\n.bg-mint { background: var(--mint); }\n.bg-ink { background: var(--ink); color: var(--white); }\n.bg-ink h1, .bg-ink h2, .bg-ink h3 { color: var(--white); }\n\n\/* Checkmark list *\/\n.checklist { list-style: none; padding: 0; margin: 0; }\n.checklist li {\n padding: 10px 0 10px 34px;\n position: relative;\n line-height: 1.55;\n font-size: 1rem;\n}\n.checklist li::before {\n content: '';\n position: absolute; left: 0; top: 14px;\n width: 20px; height: 20px;\n background: var(--emerald);\n border-radius: 50%;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 12 12'><path fill='none' stroke='white' stroke-width='2' stroke-linecap='round' stroke-linejoin='round' d='M2.5 6.5 L5 9 L9.5 3.5'\/><\/svg>\");\n background-size: 13px 13px;\n background-position: center;\n background-repeat: no-repeat;\n}\n\n\/* Forms *\/\n.form-row { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 20px; }\n@media (max-width: 600px) { .form-row { grid-template-columns: 1fr; gap: 16px; margin-bottom: 16px; } }\n\n.field {\n display: block;\n width: 100%;\n padding: 15px 17px;\n font-family: inherit;\n font-size: 1.02rem;\n color: var(--ink-body);\n background: var(--white);\n border: 1.5px solid var(--line-strong);\n border-radius: var(--r-md);\n transition: border-color .15s ease;\n}\n.field:focus { outline: 0; border-color: var(--indigo); box-shadow: 0 0 0 3px rgba(28,22,145,.12); }\n.label {\n display: block;\n font-size: .92rem;\n font-weight: 600;\n color: var(--ink-body);\n margin-bottom: 8px;\n letter-spacing: .01em;\n}\ntextarea.field { min-height: 160px; resize: vertical; }\n\n\/* Scientific accent \u2014 small molecule chip *\/\n.mol-chip {\n display: inline-flex; align-items: baseline; gap: 6px;\n padding: 4px 11px;\n background: var(--ink);\n color: var(--white);\n border-radius: 4px;\n font-family: var(--f-mono);\n font-size: .85rem;\n font-weight: 500;\n letter-spacing: .02em;\n}\n\n\/* Accordion \/ expandable *\/\n.timeline {\n position: relative;\n padding-left: 32px;\n}\n.timeline::before {\n content: ''; position: absolute;\n left: 7px; top: 6px; bottom: 6px;\n width: 2px;\n background: linear-gradient(180deg, var(--indigo) 0%, var(--violet) 50%, var(--magenta) 100%);\n border-radius: 2px;\n}\n.timeline-item { position: relative; padding-bottom: 32px; }\n.timeline-item::before {\n content: ''; position: absolute;\n left: -32px; top: 6px;\n width: 16px; height: 16px;\n background: var(--white);\n border: 3px solid var(--indigo);\n border-radius: 50%;\n}\n.timeline-item:last-child { padding-bottom: 0; }\n.timeline-date {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n text-transform: uppercase;\n letter-spacing: .06em;\n margin-bottom: 6px;\n}\n.timeline-title { font-weight: 700; font-size: 1.15rem; color: var(--ink); margin-bottom: 6px; }\n.timeline-body { color: var(--ink-muted); font-size: 1rem; line-height: 1.6; }\n\n\/* Legal\/disclaimer microcopy *\/\n.fine { font-size: .88rem; color: var(--ink-muted); line-height: 1.6; }\n\n\/* ========== RESPONSIVE FINE-TUNING ========== *\/\n\n\/* Tablet tuning *\/\n@media (max-width: 1024px) {\n .hero { padding: clamp(4rem, 8vw, 6rem) 0 clamp(3rem, 6vw, 5rem); }\n}\n\n\/* Mobile tuning \u2014 < 640px *\/\n@media (max-width: 640px) {\n h1 { font-size: clamp(2.1rem, 9vw, 3rem); }\n h2 { font-size: clamp(1.65rem, 6.5vw, 2.2rem); }\n h3 { font-size: 1.25rem; }\n .lead { font-size: 1.08rem; }\n .hero { padding: 3.5rem 0 3rem; }\n .hero .lead { font-size: 1.08rem; }\n .section { padding: 3.5rem 0; }\n .section-sm { padding: 2.5rem 0; }\n .card, .pillar { padding: 24px; }\n .btn { padding: 14px 22px; font-size: .95rem; }\n .stat-value { font-size: clamp(2.2rem, 10vw, 2.8rem); }\n}\n\n\/* Small mobile \u2014 < 380px *\/\n@media (max-width: 380px) {\n body { font-size: 15px; }\n h1 { font-size: 2rem; }\n .wrap, .narrow { padding: 0 16px; }\n .hero { padding: 3rem 0 2.5rem; }\n}\n\n\/* Safety: horizontal overflow prevention *\/\nhtml, body { overflow-x: hidden; max-width: 100%; }\nimg, svg, video { max-width: 100%; height: auto; }\ntable { max-width: 100%; }\n\n<\/style>\n<\/head>\n<body>\n\n<header class=\"nav\">\n <div class=\"nav-inner\">\n <a class=\"nav-brand\" href=\"index.html\"><img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\"><\/a>\n <nav><ul class=\"nav-links\">\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"investors.html\" class=\"is-active\">Investors<\/a><\/li>\n <\/ul><\/nav>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n\n <div class=\"nav-mobile\">\n <ul>\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"investors.html\" class=\"is-active\">Investors<\/a><\/li>\n <\/ul>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n<\/header>\n\n\n<section class=\"hero\" style=\"padding:clamp(4rem,7vw,6rem) 0;\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Investors<\/span>\n <h1 style=\"margin-top:22px;\">A late-stage, first-in-class oral asset in a<br><em>$15B+ market.<\/em><\/h1>\n <p class=\"lead\" style=\"margin-top:22px;\">\n Azuriya Pharma is positioned to rapidly prove a novel oral IBD mechanism \u2014 leveraging\n ~400 patients of prior human safety, preclinical validation across acute and chronic\n colitis models, and composition of matter protection through 2044+.\n <\/p>\n <div style=\"margin-top:36px; display:flex; gap:14px; flex-wrap:wrap;\">\n <a href=\"contact.html#investors\" class=\"btn btn-emerald\">Request Investor Package \u2192<\/a>\n <a href=\"#financing\" class=\"btn btn-light\">Financing Scenarios<\/a>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <div style=\"max-width:720px;\">\n <span class=\"eyebrow\">Investment Thesis<\/span>\n <h2 class=\"mt-2\">Six reasons Azuriya is differentiated.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <\/div>\n\n <div class=\"pillars mt-4\">\n <article class=\"pillar\">\n <div class=\"pillar-num\">01 \u00b7 Market<\/div>\n <h3 class=\"pillar-title\">$15B+ market with sustained unmet need<\/h3>\n <p class=\"pillar-body\">More than half of 7M global IBD patients fail to reach durable remission. Attractive Phase 2\/3 M&A interest from global pharma.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">02 \u00b7 MOA<\/div>\n <h3 class=\"pillar-title\">Upstream \u00b7 combinable \u00b7 non-immunosuppressive<\/h3>\n <p class=\"pillar-body\">APE1\/Ref-1 sits upstream of NF-\u03baB, HIF-1\u03b1, STAT3, and AP-1 \u2014 designed to combine with every approved class without mechanistic redundancy.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">03 \u00b7 Safety<\/div>\n <h3 class=\"pillar-title\">~400 patients de-risk the program<\/h3>\n <p class=\"pillar-body\">Clean safety profile across liver, oncology, and diabetic retinopathy. No treatment-related SAEs; 600 mg\/day RP2D established.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">04 \u00b7 Preclinical<\/div>\n <h3 class=\"pillar-title\">Compelling efficacy across IBD models<\/h3>\n <p class=\"pillar-body\">Ref-1 compares favorably to approved\/emerging MOAs across acute DSS, chronic Winnie, adoptive transfer, and T-cell transfer.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">05 \u00b7 Patents<\/div>\n <h3 class=\"pillar-title\">Composition of matter through 2044+<\/h3>\n <p class=\"pillar-body\">7 patent families covering compound, methods, and formulation. Calcium-salt polymorph IP through 2044 before 5-year PTE.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">06 \u00b7 POC Plan<\/div>\n <h3 class=\"pillar-title\">Rapid Phase 2a in Australia<\/h3>\n <p class=\"pillar-body\">$1M USD POC leveraging AUS R&D incentives. 6-month FPI, 12-month topline data, then pivot to FDA-approvable Phase 2b.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Market Opportunity<\/span>\n <h2 class=\"mt-2\">A $15B+ market ready for new combinable oral MOAs.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"grid-2 mt-4\" style=\"align-items:center;\">\n <div class=\"stats\" style=\"grid-template-columns:1fr 1fr;\">\n <div class=\"stat\">\n <div class=\"stat-value\">7M<\/div>\n <div class=\"stat-label\">Global IBD Patients<\/div>\n <\/div>\n <div class=\"stat\">\n <div class=\"stat-value\">$15B+<\/div>\n <div class=\"stat-label\">Global Market Size<\/div>\n <\/div>\n <div class=\"stat\" style=\"border-bottom:0;\">\n <div class=\"stat-value\">8%<\/div>\n <div class=\"stat-label\">CAGR Through 2030<\/div>\n <\/div>\n <div class=\"stat\" style=\"border-bottom:0; border-right:0;\">\n <div class=\"stat-value\">50%+<\/div>\n <div class=\"stat-label\">Fail 1L Therapy<\/div>\n <\/div>\n <\/div>\n <div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.6rem; letter-spacing:-0.02em;\">US Population \u2014 Indication Breakdown<\/h3>\n <div class=\"mt-3\" style=\"background:var(--white); border:1px solid var(--line); border-radius:var(--r-md); overflow:hidden;\">\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px; border-bottom:1px solid var(--line);\">\n <span style=\"font-weight:600;\">IBD (total)<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">3+ million<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px; border-bottom:1px solid var(--line);\">\n <span>Ulcerative Colitis<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">1+ million<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px; border-bottom:1px solid var(--line);\">\n <span>Crohn's Disease<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">~1 million<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px;\">\n <span>Non-GI Implications<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">~1 million<\/span>\n <\/div>\n <\/div>\n <p class=\"fine mt-2\">Sources: CDC; gastrojournal.org; PubMed 15168363.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Robust Pharma M&A in IBD<\/span>\n <h2 class=\"mt-2\">$25B+ invested by big pharma across recent IBD transactions.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n These transactions highlight strategic interest in new mechanisms beyond traditional\n TNF \/ IL-12\/23 inhibition \u2014 including TREM1, NLRX1, TL1A, S1P, and integrin targets. The\n appeal lies in both differentiated biology and combination potential with existing\n therapies, with an increasing focus on orals.\n <\/p>\n\n <div class=\"mt-4\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr>\n <th>Date<\/th>\n <th>Stage<\/th>\n <th>Deal ($M)<\/th>\n <th>Acquired<\/th>\n <th>Acquirer<\/th>\n <th>Indication<\/th>\n <th>Asset \/ MOA<\/th>\n <th>Admin<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Jun '24<\/td><td>Phase 1a<\/td><td><strong>$250<\/strong><\/td>\n <td>Celsius Therapeutics<\/td><td>AbbVie<\/td>\n <td>Healthy volunteers<\/td>\n <td>CEL383 anti-TREM1 mAb<\/td><td>IV<\/td>\n <\/tr>\n <tr>\n <td>May '24<\/td><td>Phase 2a<\/td><td><strong>$138<\/strong><\/td>\n <td>Landos Biopharma<\/td><td>AbbVie<\/td>\n <td>UC<\/td>\n <td>NX-13 NLRX1 agonist small molecule<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Jun '23<\/td><td>Phase 2a<\/td><td><strong>$350<\/strong><\/td>\n <td>Spyre Therapeutics<\/td><td>Series B<\/td>\n <td>UC, Crohn's<\/td>\n <td>Antibody platform anti-TL1A \/ IL-23 \/ \u03b14\u03b27<\/td><td>SC<\/td>\n <\/tr>\n <tr>\n <td>May '22<\/td><td>Phase 2a<\/td><td><strong>$1,100<\/strong><\/td>\n <td>Protagonist (PTG-200)<\/td><td>Johnson & Johnson<\/td>\n <td>IBD<\/td>\n <td>PN-235 IL-23R antagonist peptide<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Jul '24<\/td><td>Phase 2b<\/td><td><strong>$3,200<\/strong><\/td>\n <td>Morphic Therapeutic<\/td><td>Eli Lilly<\/td>\n <td>UC, Crohn's<\/td>\n <td>MORF-057 \u03b14\u03b27 inhibitor small molecule<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Dec '23<\/td><td>Phase 2b<\/td><td><strong>$7,100<\/strong><\/td>\n <td>Telavant (Roivant\/Pfizer)<\/td><td>Roche<\/td>\n <td>IBD<\/td>\n <td>RVT-3101 anti-TL1A mAb<\/td><td>SC<\/td>\n <\/tr>\n <tr>\n <td>Jun '23<\/td><td>Phase 2b<\/td><td><strong>$10,800<\/strong><\/td>\n <td>Prometheus Biosciences<\/td><td>Merck<\/td>\n <td>UC, Crohn's<\/td>\n <td>PRA023 anti-TL1A mAb<\/td><td>IV\/SC<\/td>\n <\/tr>\n <tr>\n <td>Apr '23<\/td><td>Phase 3<\/td><td><strong>$6,700<\/strong><\/td>\n <td>Arena Pharmaceuticals<\/td><td>Pfizer<\/td>\n <td>UC<\/td>\n <td>Etrasimod selective S1P modulator<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Oct '23<\/td><td>Phase 3<\/td><td><strong>$750<\/strong><\/td>\n <td>Abivax<\/td><td>Follow-on<\/td>\n <td>UC<\/td>\n <td>Obefazimod miR-124 enhancer<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <p class=\"fine mt-3\">Big pharma has invested over $25 billion to capture the next wave of IBD innovation, with an increasing premium for differentiated oral assets.<\/p>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-lavender\" id=\"financing\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Financing Scenarios<\/span>\n <h2 class=\"mt-2\">A staged capital plan to NDA.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n Three capital rounds through NDA filing, each aligned to a value-creating clinical or\n regulatory milestone. Structures flex with investor interest and partnership dynamics.\n <\/p>\n\n <div class=\"grid-3 mt-4\">\n <article class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-indigo\">Round 1 \u00b7 2Q 2026<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">$8M \u2013 $20M+<\/h3>\n <p class=\"fine mt-2\">Common stock or convertible note. Funds 12\u201324 months of operations through IND transfer, CTN submission, and Phase 2a initiation.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.9rem;\">\n <li>Newco formation & IU licensing<\/li>\n <li>GMP Ca-salt drug substance \/ drug product<\/li>\n <li>Phase 2a site contracting & enrollment<\/li>\n <\/ul>\n <\/article>\n <article class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-violet\">Round 2 \u00b7 2027<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">$20M \u2013 $30M+<\/h3>\n <p class=\"fine mt-2\">Crossover, PIPE \/ reverse merger, or IPO round. Funds Phase 2b initiation alongside Phase 2a topline readout.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.9rem;\">\n <li>Phase 2a topline data<\/li>\n <li>Phase 2b protocol & site selection<\/li>\n <li>Strategic partnership discussions<\/li>\n <\/ul>\n <\/article>\n <article class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-new\">Round 3 \u00b7 2028<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">$50M \u2013 $100M+<\/h3>\n <p class=\"fine mt-2\">IPO round or regional partnership. Funds Phase 2b through to topline data and positions the asset for Phase 3 or strategic exit.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.9rem;\">\n <li>Nasdaq listing pathway<\/li>\n <li>Phase 2b topline + FDA end-of-P2<\/li>\n <li>Global commercial strategy<\/li>\n <\/ul>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Exit Strategy<\/span>\n <h2 class=\"mt-2\">Multiple paths to liquidity at inflection points.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n The IBD market presents multiple liquidity pathways, driven by sustained M&A\n activity, strategic partnerships, and strong public market interest in differentiated\n oral assets.\n <\/p>\n\n <div class=\"grid-3 mt-4\">\n <article class=\"card\">\n <span class=\"badge badge-new\">Path A<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">Strategic Acquisition<\/h3>\n <div style=\"margin:18px 0; padding:14px 18px; background:var(--cloud); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-size:.78rem; color:var(--ink-muted); text-transform:uppercase; letter-spacing:.1em;\">Target valuation<\/div>\n <div style=\"font-family:var(--f-display); font-size:1.8rem; font-weight:500; color:var(--indigo); letter-spacing:-0.02em;\">$500M \u2013 $1B+<\/div>\n <div class=\"fine mt-1\">Timeline: 24+ months<\/div>\n <\/div>\n <p class=\"fine\">Pharma acquires a differentiated oral asset with Phase 2 POC data \u2014 consistent with recent IBD transactions.<\/p>\n <\/article>\n\n <article class=\"card\">\n <span class=\"badge badge-violet\">Path B<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">Development Partner<\/h3>\n <div style=\"margin:18px 0; padding:14px 18px; background:var(--cloud); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-size:.78rem; color:var(--ink-muted); text-transform:uppercase; letter-spacing:.1em;\">Deal structure<\/div>\n <div style=\"font-family:var(--f-display); font-size:1.8rem; font-weight:500; color:var(--indigo); letter-spacing:-0.02em;\">$150M+ upfront<\/div>\n <div class=\"fine mt-1\">Timeline: 12+ months \u00b7 plus milestones & royalties<\/div>\n <\/div>\n <p class=\"fine\">Upfront + development\/commercial milestones + double-digit royalty structure. Preserves upside with strategic partner resources.<\/p>\n <\/article>\n\n <article class=\"card\">\n <span class=\"badge badge-indigo\">Path C<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">Public Listing (IPO)<\/h3>\n <div style=\"margin:18px 0; padding:14px 18px; background:var(--cloud); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-size:.78rem; color:var(--ink-muted); text-transform:uppercase; letter-spacing:.1em;\">Target market cap<\/div>\n <div style=\"font-family:var(--f-display); font-size:1.8rem; font-weight:500; color:var(--indigo); letter-spacing:-0.02em;\">$200M+<\/div>\n <div class=\"fine mt-1\">Timeline: 12 \u2013 24 months<\/div>\n <\/div>\n <p class=\"fine\">Nasdaq listing to independently fund Phase 3. Maintains company independence and full economics on a first-in-class platform.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Competitive Benchmarking<\/span>\n <h2 class=\"mt-2\">APX3330 vs. approved & emerging IBD MOAs.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n Unlike single-target approved therapies, APX3330 converges on multiple validated IBD nodes \u2014 orally, safely, and with no biosimilar risk.\n <\/p>\n\n <div class=\"mt-4\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr>\n <th>Attribute<\/th>\n <th style=\"background:var(--indigo); color:var(--white);\">APX3330<\/th>\n <th>Obefazimod (Abivax)<\/th>\n <th>Entyvio<\/th>\n <th>Rinvoq<\/th>\n <th>Skyrizi \/ Tremfya<\/th>\n <th>PRA023 \/ TL1A<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td><strong>Target<\/strong><\/td>\n <td><strong style=\"color:var(--indigo);\">Ref-1<\/strong><\/td>\n <td>miR-124 \/ TNF\u03b1<\/td>\n <td>\u03b14\u03b27<\/td>\n <td>JAK<\/td>\n <td>IL-23<\/td>\n <td>TL1A<\/td>\n <\/tr>\n <tr>\n <td><strong>Upstream MOA<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Gene transcription<\/td>\n <td>Post-transcriptional<\/td>\n <td>Immune modulation<\/td>\n <td>Signal transduction<\/td>\n <td>Cytokine suppression<\/td>\n <td>Immune modulation<\/td>\n <\/tr>\n <tr>\n <td><strong>Oral<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>Injectable<\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>Injectable<\/td>\n <td>Injectable<\/td>\n <\/tr>\n <tr>\n <td><strong>Neuroprotection<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td>\n <\/tr>\n <tr>\n <td><strong>Hematopoiesis Protection<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td>\n <\/tr>\n <tr>\n <td><strong>Exclusivity Through<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">2043+<\/td>\n <td>2035<\/td>\n <td style=\"color:var(--ink-muted);\">2028<\/td>\n <td>2037<\/td>\n <td>2031 \u2013 2032<\/td>\n <td>2035<\/td>\n <\/tr>\n <tr>\n <td><strong>Safety Profile<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">~400 patients \u00b7 clean<\/td>\n <td>Phase 3 positive<\/td>\n <td>Approved<\/td>\n <td style=\"color:var(--magenta);\">Black box<\/td>\n <td>Approved<\/td>\n <td>Phase 2\/3<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <p class=\"fine mt-3\">Data confirmation in process. See data room for complete competitive analysis.<\/p>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Operational & Financing Milestones<\/span>\n <h2 class=\"mt-2\">Path to value creation.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"timeline mt-4\">\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">1H 2026 \u00b7 Newco Launch<\/div>\n <div class=\"timeline-title\">Company formation & asset consolidation<\/div>\n <div class=\"timeline-body\">Secure APX IP from OPUS \u00b7 finalize IU licensing \u00b7 close open diligence items \u00b7 recruit KOLs \u00b7 first financing round ($8\u201320M).<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2H 2026 \u00b7 Trial Prep<\/div>\n <div class=\"timeline-title\">IND transfer & Australian CTN<\/div>\n <div class=\"timeline-body\">Transfer IND with FDA \u00b7 AUS subsidiary and CTN submission \u00b7 preclinical combination studies \u00b7 site selection and contracting \u00b7 GMP Ca-salt drug substance and drug product.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">1H 2027 \u00b7 Phase 2a + 2b Start<\/div>\n <div class=\"timeline-title\">Patient enrollment begins<\/div>\n <div class=\"timeline-body\">Open-label enrollment \u00b7 safety monitoring \u00b7 early open-label data \u00b7 any preclinical studies required for Phase 3 readiness.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2H 2027 \u00b7 Phase 2a Topline<\/div>\n <div class=\"timeline-title\">Proof of concept readout<\/div>\n <div class=\"timeline-body\">Primary and secondary endpoints \u00b7 safety data \u00b7 biomarker signals \u00b7 publications \u00b7 active strategic partnership discussions.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2028 \u00b7 Phase 2b Topline<\/div>\n <div class=\"timeline-title\">FDA-approvable endpoints readout<\/div>\n <div class=\"timeline-body\">Full Phase 2b efficacy and safety data \u00b7 publications \u00b7 End-of-Phase-2 meeting preparation \u00b7 position for strategic exit, Phase 3, or NDA planning.<\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-ink\" style=\"padding:clamp(4rem,8vw,6rem) 0;\">\n <div class=\"wrap text-center\" style=\"max-width:720px;\">\n <span class=\"eyebrow\" style=\"color:var(--emerald-bright);\">Investor Inquiries<\/span>\n <h2 style=\"margin-top:22px;\">Access the full investor package.<\/h2>\n <p class=\"lead\" style=\"color:rgba(255,255,255,.75); margin:22px auto 32px;\">\n Request the full deck, data room, and a conversation with the Azuriya leadership team.\n Confidential materials available under NDA.\n <\/p>\n <div style=\"display:flex; gap:14px; justify-content:center; flex-wrap:wrap;\">\n <a href=\"contact.html#investors\" class=\"btn btn-emerald\">Request Package \u2192<\/a>\n <a href=\"contact.html\" class=\"btn btn-light\">Schedule a Call<\/a>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section section-sm\">\n <div class=\"wrap\">\n <p class=\"fine\">\n <strong>Forward-Looking Statements.<\/strong> This page contains forward-looking statements\n regarding Azuriya Pharma's clinical development plans, financing strategy, and potential\n exit pathways, including expected timelines and valuations. Actual results and outcomes\n may differ materially from those contemplated. APX3330 is an investigational compound and\n has not been approved by the FDA, EMA, or any other regulatory authority. Past transactions\n and valuations cited are for reference only and do not guarantee similar outcomes.\n Nothing on this page constitutes an offer to sell or a solicitation to buy any security.\n <\/p>\n <\/div>\n<\/section>\n\n<footer class=\"foot\">\n <div class=\"wrap\">\n <div class=\"foot-grid\">\n <div class=\"foot-brand\">\n <img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\">\n <p style=\"max-width:340px; font-size:.95rem; line-height:1.6;\">A late-stage, first-in-class oral small-molecule therapy targeting root causes of Inflammatory Bowel Disease through upstream modulation.<\/p>\n <\/div>\n <div><h4>Science<\/h4><ul>\n <li><a href=\"science.html\">Mechanism of Action<\/a><\/li>\n <li><a href=\"science.html#pipeline\">Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Company<\/h4><ul>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"about.html#team\">Team<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Contact<\/h4><ul>\n <li><a href=\"contact.html\">General Inquiries<\/a><\/li>\n <li><a href=\"contact.html#partnership\">Partnerships<\/a><\/li>\n <li><a href=\"contact.html#investors\">Investor Relations<\/a><\/li>\n <\/ul><\/div>\n <\/div>\n <div class=\"foot-copy\">\n <span>\u00a9 2026 Azuriya Pharma. All rights reserved.<\/span>\n <span>APX3330 is an investigational compound and has not been approved by any regulatory authority.<\/span>\n <\/div>\n <\/div>\n<\/footer>\n\n\n<script>\n(function(){\n var nav = document.querySelector('.nav');\n var toggle = document.querySelector('.nav-toggle');\n if (!nav || !toggle) return;\n toggle.addEventListener('click', function(){ nav.classList.toggle('is-open'); });\n var mobileLinks = nav.querySelectorAll('.nav-mobile a');\n mobileLinks.forEach(function(a){\n a.addEventListener('click', function(){ nav.classList.remove('is-open'); });\n });\n})();\n<\/script>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Investors \u2014 Azuriya Pharma Home Science & Pipeline Publications About Investors Contact Home Science & Pipeline Publications About Investors Contact Investors A late-stage, first-in-class oral asset in a$15B+ market. Azuriya Pharma is positioned to rapidly prove a novel oral IBD mechanism \u2014 leveraging ~400 patients of prior human safety, preclinical validation across acute and chronic …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-12","page","type-page","status-publish","hentry","post","without-featured-image"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/12","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12"}],"version-history":[{"count":0,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/12\/revisions"}],"wp:attachment":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n\t\t\t\t\t\n\n\n\n\n\nInvestors \u2014 Azuriya Pharma<\/title>\n<meta name=\"description\" content=\"Azuriya Pharma investor overview: $15B+ IBD market, multiple paths to liquidity, late-stage oral asset with composition of matter IP through 2044+.\">\n<link rel=\"icon\" href=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\">\n<style>\n\/* ============================================================\n Azuriya Pharma \u2014 Website Design System\n Derived from the Azuriya logo: indigo \/ emerald \/ violet gradient\n ============================================================ *\/\n\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Fraunces:ital,opsz,wght@0,9..144,300..900;1,9..144,300..900&family=Manrope:wght@300;400;500;600;700;800&family=JetBrains+Mono:wght@400;500;600&display=swap');\n\n:root {\n \/* === BRAND CORE (from logo) === *\/\n --indigo: #1C1691; \/* Primary \u2014 \"Azuriya\" wordmark *\/\n --indigo-deep: #14107A; \/* Hover \/ pressed *\/\n --ink: #0B0A4E; \/* Deep background for hero \/ footer *\/\n --emerald: #00A03C; \/* Secondary \u2014 green arc *\/\n --emerald-bright:#14BE54; \/* Hover highlight *\/\n --violet: #8B4FD8; \/* Accent \u2014 gradient start *\/\n --magenta: #C850DC; \/* Accent \u2014 gradient end *\/\n\n \/* === TINTS & SURFACES === *\/\n --cloud: #F7F8FC;\n --lavender: #F0EBFA;\n --mint: #E6F7EC;\n --white: #FFFFFF;\n\n \/* === TEXT === *\/\n --ink-body: #1A1A2E; \/* body text \u2014 indigo-tinted charcoal *\/\n --ink-muted: #555566;\n --ink-subtle: #8A8A9C;\n\n \/* === LINES === *\/\n --line: #E4E4F0;\n --line-strong: #C8C8DC;\n\n \/* === EFFECTS === *\/\n --gradient-accent: linear-gradient(90deg, var(--violet) 0%, var(--magenta) 100%);\n --gradient-brand: linear-gradient(135deg, var(--indigo) 0%, var(--violet) 100%);\n --gradient-hero: linear-gradient(135deg, #0B0A4E 0%, #1C1691 60%, #2E1E8C 100%);\n\n --shadow-sm: 0 1px 2px rgba(11,10,78,0.04), 0 1px 3px rgba(11,10,78,0.06);\n --shadow-md: 0 4px 12px rgba(11,10,78,0.06), 0 8px 24px rgba(11,10,78,0.04);\n --shadow-lg: 0 12px 32px rgba(11,10,78,0.08), 0 24px 64px rgba(11,10,78,0.06);\n\n \/* === RADII === *\/\n --r-sm: 4px;\n --r-md: 8px;\n --r-lg: 14px;\n --r-xl: 22px;\n\n \/* === TYPE SCALE === *\/\n --f-display: 'Fraunces', 'Georgia', serif;\n --f-sans: 'Manrope', -apple-system, BlinkMacSystemFont, sans-serif;\n --f-mono: 'JetBrains Mono', 'SF Mono', Menlo, monospace;\n}\n\n\/* ========== RESET ========== *\/\n*, *::before, *::after { box-sizing: border-box; }\nhtml { -webkit-text-size-adjust: 100%; scroll-behavior: smooth; }\nbody {\n margin: 0;\n font-family: var(--f-sans);\n font-size: 17px;\n line-height: 1.65;\n color: var(--ink-body);\n background: var(--white);\n font-feature-settings: 'ss01', 'cv11';\n -webkit-font-smoothing: antialiased;\n -moz-osx-font-smoothing: grayscale;\n}\n@media (min-width: 1600px) {\n body { font-size: 18px; }\n}\n@media (max-width: 640px) {\n body { font-size: 16px; line-height: 1.6; }\n}\nimg { max-width: 100%; display: block; }\na { color: var(--indigo); text-decoration: none; transition: color .15s ease; }\na:hover { color: var(--violet); }\nbutton { font-family: inherit; cursor: pointer; }\n\n\/* ========== TYPOGRAPHY ========== *\/\nh1, h2, h3, h4 {\n font-family: var(--f-display);\n font-weight: 500;\n line-height: 1.12;\n letter-spacing: -0.02em;\n color: var(--ink);\n margin: 0 0 .5em;\n font-variation-settings: 'opsz' 144;\n}\nh1 { font-size: clamp(2.6rem, 5.5vw, 5rem); line-height: 1.06; }\nh2 { font-size: clamp(2rem, 4vw, 3.2rem); line-height: 1.12; }\nh3 { font-size: clamp(1.4rem, 2.4vw, 1.75rem); font-family: var(--f-sans); font-weight: 700; letter-spacing: -0.01em; line-height: 1.25; }\nh4 { font-size: 1.15rem; font-family: var(--f-sans); font-weight: 600; letter-spacing: 0; }\n\n.eyebrow {\n font-family: var(--f-sans);\n font-size: .88rem;\n font-weight: 700;\n text-transform: uppercase;\n letter-spacing: .18em;\n color: var(--emerald);\n display: inline-flex;\n align-items: center;\n gap: .55rem;\n}\n.eyebrow::before {\n content: '';\n display: inline-block;\n width: 22px;\n height: 1px;\n background: var(--emerald);\n}\n\n.lead { font-size: clamp(1.15rem, 1.4vw, 1.4rem); line-height: 1.55; color: var(--ink-muted); max-width: 62ch; }\n.mono { font-family: var(--f-mono); font-size: .92em; letter-spacing: -.01em; }\n\n\/* Italic emphasis in serif headlines gets a violet tint *\/\nh1 em, h2 em, .serif em {\n font-style: italic;\n font-weight: 400;\n background: var(--gradient-accent);\n -webkit-background-clip: text;\n background-clip: text;\n -webkit-text-fill-color: transparent;\n}\n\n\/* ========== LAYOUT ========== *\/\n.wrap { max-width: 1320px; margin: 0 auto; padding: 0 32px; }\n.narrow { max-width: 960px; margin: 0 auto; padding: 0 32px; }\n.section { padding: clamp(4rem, 8vw, 8rem) 0; }\n.section-sm { padding: clamp(2.5rem, 5vw, 4.5rem) 0; }\n@media (max-width: 640px) {\n .wrap, .narrow { padding: 0 20px; }\n}\n\n\/* ========== NAV ========== *\/\n.nav {\n position: sticky; top: 0; z-index: 50;\n background: rgba(255,255,255,.88);\n backdrop-filter: saturate(180%) blur(12px);\n -webkit-backdrop-filter: saturate(180%) blur(12px);\n border-bottom: 1px solid var(--line);\n}\n.nav-inner {\n max-width: 1320px; margin: 0 auto;\n padding: 20px 32px;\n display: flex; align-items: center; justify-content: space-between;\n gap: 32px;\n}\n.nav-brand {\n display: flex; align-items: center; gap: 10px;\n text-decoration: none;\n}\n.nav-brand img { height: 44px; width: auto; }\n.nav-links {\n display: flex; gap: 32px; align-items: center;\n list-style: none; margin: 0; padding: 0;\n}\n.nav-links a {\n font-size: 1.02rem;\n font-weight: 500;\n color: var(--ink-body);\n position: relative;\n padding: 4px 0;\n}\n.nav-links a:hover { color: var(--indigo); }\n.nav-links a.is-active { color: var(--indigo); }\n.nav-links a.is-active::after {\n content: ''; position: absolute; left: 0; right: 0; bottom: -4px;\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n}\n.nav-cta {\n padding: 12px 22px;\n border-radius: 999px;\n background: var(--indigo);\n color: var(--white) !important;\n font-weight: 600;\n font-size: .98rem;\n transition: all .15s ease;\n}\n.nav-cta:hover { background: var(--indigo-deep); transform: translateY(-1px); }\n\n.nav-toggle { display: none; background: none; border: 0; padding: 6px; cursor: pointer; }\n.nav-toggle svg { width: 28px; height: 28px; color: var(--indigo); }\n\n\/* Mobile drawer: revealed when .nav has .is-open *\/\n.nav-mobile {\n display: none;\n border-top: 1px solid var(--line);\n background: var(--white);\n padding: 16px 32px 24px;\n}\n.nav-mobile ul { list-style: none; margin: 0; padding: 0; }\n.nav-mobile li { border-bottom: 1px solid var(--line); }\n.nav-mobile li:last-child { border-bottom: 0; }\n.nav-mobile a {\n display: block;\n padding: 16px 0;\n font-size: 1.12rem;\n font-weight: 500;\n color: var(--ink);\n}\n.nav-mobile a:hover, .nav-mobile a.is-active { color: var(--indigo); }\n.nav-mobile .nav-cta {\n display: inline-block;\n margin-top: 20px;\n color: var(--white) !important;\n}\n.nav.is-open .nav-mobile { display: block; }\n\n@media (max-width: 1024px) {\n .nav-links { display: none; }\n .nav-toggle { display: block; }\n .nav-inner > .nav-cta { display: none; } \/* Contact CTA moves into drawer *\/\n}\n@media (max-width: 640px) {\n .nav-inner { padding: 16px 20px; }\n .nav-brand img { height: 38px; }\n .nav-mobile { padding: 16px 20px 24px; }\n}\n\n\/* ========== BUTTONS ========== *\/\n.btn {\n display: inline-flex; align-items: center; gap: 8px;\n padding: 16px 28px;\n border-radius: 999px;\n font-weight: 600;\n font-size: 1rem;\n text-decoration: none;\n transition: all .18s ease;\n border: 0;\n}\n.btn-primary { background: var(--indigo); color: var(--white); }\n.btn-primary:hover { background: var(--indigo-deep); color: var(--white); transform: translateY(-1px); box-shadow: var(--shadow-md); }\n\n.btn-emerald { background: var(--emerald); color: var(--white); }\n.btn-emerald:hover { background: var(--emerald-bright); color: var(--white); transform: translateY(-1px); }\n\n.btn-ghost {\n background: transparent;\n color: var(--indigo);\n border: 1.5px solid var(--line-strong);\n}\n.btn-ghost:hover { border-color: var(--indigo); background: var(--lavender); color: var(--indigo); }\n\n.btn-light {\n background: rgba(255,255,255,0.1);\n color: var(--white);\n border: 1.5px solid rgba(255,255,255,0.25);\n backdrop-filter: blur(8px);\n}\n.btn-light:hover { background: rgba(255,255,255,0.18); color: var(--white); border-color: rgba(255,255,255,0.5); }\n\n\/* ========== HERO ========== *\/\n.hero {\n position: relative;\n background: var(--gradient-hero);\n color: var(--white);\n padding: clamp(5rem, 10vw, 8rem) 0 clamp(4rem, 8vw, 6rem);\n overflow: hidden;\n}\n.hero::before {\n \/* subtle molecular network texture *\/\n content: '';\n position: absolute; inset: 0;\n background-image:\n radial-gradient(circle at 20% 30%, rgba(139,79,216,0.18) 0%, transparent 40%),\n radial-gradient(circle at 80% 70%, rgba(0,160,60,0.12) 0%, transparent 45%),\n radial-gradient(circle at 50% 100%, rgba(200,80,220,0.10) 0%, transparent 50%);\n pointer-events: none;\n}\n.hero::after {\n content: '';\n position: absolute; inset: 0;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' width='160' height='160' viewBox='0 0 160 160'><g fill='none' stroke='white' stroke-opacity='0.05' stroke-width='1'><circle cx='80' cy='80' r='3'\/><circle cx='20' cy='40' r='2'\/><circle cx='140' cy='120' r='2'\/><circle cx='40' cy='130' r='2.5'\/><circle cx='120' cy='30' r='2.5'\/><path d='M80 80 L20 40 M80 80 L140 120 M80 80 L40 130 M80 80 L120 30'\/><\/g><\/svg>\");\n background-size: 320px 320px;\n opacity: .5;\n pointer-events: none;\n}\n.hero > .wrap { position: relative; z-index: 1; }\n.hero h1 { color: var(--white); }\n.hero .eyebrow { color: #6FE5A1; }\n.hero .eyebrow::before { background: #6FE5A1; }\n.hero .lead { color: rgba(255,255,255,.85); font-size: clamp(1.2rem, 1.5vw, 1.45rem); max-width: 58ch; }\n\n\/* ========== CARD \/ PANEL ========== *\/\n.card {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 28px;\n transition: all .2s ease;\n}\n.card:hover { border-color: var(--line-strong); box-shadow: var(--shadow-md); transform: translateY(-2px); }\n.card-tint-lav { background: var(--lavender); border-color: transparent; }\n.card-tint-mint { background: var(--mint); border-color: transparent; }\n\n\/* ========== STAT STRIP ========== *\/\n.stats {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));\n gap: 0;\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n overflow: hidden;\n background: var(--white);\n}\n.stat {\n padding: 40px 32px;\n border-right: 1px solid var(--line);\n position: relative;\n}\n.stat:last-child { border-right: 0; }\n.stat-value {\n font-family: var(--f-display);\n font-size: clamp(2.4rem, 4.5vw, 3.6rem);\n font-weight: 500;\n line-height: 1;\n color: var(--indigo);\n letter-spacing: -0.03em;\n margin-bottom: 10px;\n}\n.stat-label {\n font-size: .88rem;\n text-transform: uppercase;\n letter-spacing: .12em;\n color: var(--ink-muted);\n font-weight: 600;\n}\n.stat-note { font-size: .95rem; color: var(--ink-muted); margin-top: 6px; }\n@media (max-width: 720px) {\n .stat { padding: 28px 24px; border-right: 0; border-bottom: 1px solid var(--line); }\n .stat:last-child { border-bottom: 0; }\n}\n\n\/* ========== PILLAR GRID ========== *\/\n.pillars {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));\n gap: 24px;\n}\n.pillar {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 32px;\n position: relative;\n transition: all .2s ease;\n}\n.pillar:hover { border-color: var(--indigo); transform: translateY(-3px); box-shadow: var(--shadow-md); }\n.pillar-num {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n margin-bottom: 12px;\n letter-spacing: .02em;\n}\n.pillar-title {\n font-family: var(--f-display);\n font-size: clamp(1.4rem, 1.8vw, 1.65rem);\n font-weight: 500;\n letter-spacing: -0.015em;\n color: var(--ink);\n margin: 0 0 14px;\n line-height: 1.15;\n}\n.pillar-body { font-size: 1rem; color: var(--ink-muted); line-height: 1.6; }\n@media (max-width: 640px) {\n .pillars { grid-template-columns: 1fr; gap: 16px; }\n .pillar { padding: 24px; }\n}\n\n\/* ========== TABLE ========== *\/\n.tbl-wrap { overflow-x: auto; -webkit-overflow-scrolling: touch; margin: 0 -4px; padding: 0 4px; }\n.tbl {\n width: 100%;\n border-collapse: collapse;\n font-size: 1rem;\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-md);\n overflow: hidden;\n}\n.tbl th {\n text-align: left;\n padding: 16px 20px;\n background: var(--cloud);\n border-bottom: 1px solid var(--line);\n font-size: .82rem;\n text-transform: uppercase;\n letter-spacing: .1em;\n color: var(--ink-muted);\n font-weight: 700;\n}\n.tbl td {\n padding: 16px 20px;\n border-bottom: 1px solid var(--line);\n vertical-align: top;\n}\n.tbl tr:last-child td { border-bottom: 0; }\n.tbl tr:hover td { background: var(--cloud); }\n@media (max-width: 640px) {\n .tbl { font-size: .95rem; min-width: 560px; }\n .tbl th, .tbl td { padding: 12px 14px; }\n}\n\n\/* ========== BADGES & CHIPS ========== *\/\n.badge {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 4px 11px;\n font-size: .78rem;\n font-weight: 700;\n letter-spacing: .08em;\n text-transform: uppercase;\n border-radius: 4px;\n}\n.badge-new { background: var(--emerald); color: var(--white); }\n.badge-indigo { background: var(--lavender); color: var(--indigo); }\n.badge-violet { background: linear-gradient(90deg, rgba(139,79,216,.15), rgba(200,80,220,.15)); color: var(--violet); }\n.badge-outline{ background: transparent; color: var(--ink-muted); border: 1px solid var(--line-strong); }\n\n.chip {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 6px 14px;\n font-size: .88rem;\n font-weight: 500;\n border-radius: 999px;\n background: var(--cloud);\n border: 1px solid var(--line);\n color: var(--ink-body);\n}\n.chip.is-active { background: var(--indigo); color: var(--white); border-color: var(--indigo); }\n.chip:hover:not(.is-active) { background: var(--lavender); border-color: var(--violet); color: var(--indigo); cursor: pointer; }\n\n\/* ========== SECTION DIVIDER ========== *\/\n.divider {\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n width: 60px;\n margin: 0 0 24px;\n}\n\n\/* ========== FOOTER ========== *\/\n.foot {\n background: var(--ink);\n color: rgba(255,255,255,.78);\n padding: 72px 0 32px;\n margin-top: 72px;\n}\n.foot a { color: rgba(255,255,255,.78); }\n.foot a:hover { color: var(--white); }\n.foot-grid {\n display: grid;\n grid-template-columns: 2fr 1fr 1fr 1fr;\n gap: 56px;\n margin-bottom: 56px;\n}\n.foot h4 {\n color: var(--white);\n font-size: .85rem;\n text-transform: uppercase;\n letter-spacing: .15em;\n margin: 0 0 18px;\n font-weight: 700;\n}\n.foot ul { list-style: none; padding: 0; margin: 0; }\n.foot ul li { margin-bottom: 12px; font-size: 1rem; }\n.foot-brand img { height: 54px; margin-bottom: 20px; filter: brightness(0) invert(1) opacity(.88); }\n.foot-copy {\n padding-top: 32px;\n border-top: 1px solid rgba(255,255,255,.12);\n font-size: .9rem;\n display: flex;\n justify-content: space-between;\n flex-wrap: wrap;\n gap: 16px;\n}\n@media (max-width: 900px) {\n .foot-grid { grid-template-columns: 1fr 1fr; gap: 36px; }\n}\n@media (max-width: 520px) {\n .foot-grid { grid-template-columns: 1fr; gap: 32px; }\n .foot { padding: 56px 0 24px; }\n}\n\n\/* ========== UTILS ========== *\/\n.grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 56px; }\n.grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 28px; }\n.grid-4 { display: grid; grid-template-columns: repeat(4, 1fr); gap: 24px; }\n@media (max-width: 1024px) {\n .grid-4 { grid-template-columns: repeat(2, 1fr); }\n}\n@media (max-width: 800px) {\n .grid-2, .grid-3 { grid-template-columns: 1fr; gap: 32px; }\n}\n@media (max-width: 640px) {\n .grid-4 { grid-template-columns: 1fr; gap: 16px; }\n}\n\n.text-center { text-align: center; }\n.mt-1 { margin-top: 8px; } .mt-2 { margin-top: 16px; } .mt-3 { margin-top: 24px; } .mt-4 { margin-top: 40px; } .mt-5 { margin-top: 64px; }\n.mb-1 { margin-bottom: 8px; } .mb-2 { margin-bottom: 16px; } .mb-3 { margin-bottom: 24px; } .mb-4 { margin-bottom: 40px; }\n\n\/* Tint backgrounds for sections *\/\n.bg-cloud { background: var(--cloud); }\n.bg-lavender { background: var(--lavender); }\n.bg-mint { background: var(--mint); }\n.bg-ink { background: var(--ink); color: var(--white); }\n.bg-ink h1, .bg-ink h2, .bg-ink h3 { color: var(--white); }\n\n\/* Checkmark list *\/\n.checklist { list-style: none; padding: 0; margin: 0; }\n.checklist li {\n padding: 10px 0 10px 34px;\n position: relative;\n line-height: 1.55;\n font-size: 1rem;\n}\n.checklist li::before {\n content: '';\n position: absolute; left: 0; top: 14px;\n width: 20px; height: 20px;\n background: var(--emerald);\n border-radius: 50%;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 12 12'><path fill='none' stroke='white' stroke-width='2' stroke-linecap='round' stroke-linejoin='round' d='M2.5 6.5 L5 9 L9.5 3.5'\/><\/svg>\");\n background-size: 13px 13px;\n background-position: center;\n background-repeat: no-repeat;\n}\n\n\/* Forms *\/\n.form-row { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 20px; }\n@media (max-width: 600px) { .form-row { grid-template-columns: 1fr; gap: 16px; margin-bottom: 16px; } }\n\n.field {\n display: block;\n width: 100%;\n padding: 15px 17px;\n font-family: inherit;\n font-size: 1.02rem;\n color: var(--ink-body);\n background: var(--white);\n border: 1.5px solid var(--line-strong);\n border-radius: var(--r-md);\n transition: border-color .15s ease;\n}\n.field:focus { outline: 0; border-color: var(--indigo); box-shadow: 0 0 0 3px rgba(28,22,145,.12); }\n.label {\n display: block;\n font-size: .92rem;\n font-weight: 600;\n color: var(--ink-body);\n margin-bottom: 8px;\n letter-spacing: .01em;\n}\ntextarea.field { min-height: 160px; resize: vertical; }\n\n\/* Scientific accent \u2014 small molecule chip *\/\n.mol-chip {\n display: inline-flex; align-items: baseline; gap: 6px;\n padding: 4px 11px;\n background: var(--ink);\n color: var(--white);\n border-radius: 4px;\n font-family: var(--f-mono);\n font-size: .85rem;\n font-weight: 500;\n letter-spacing: .02em;\n}\n\n\/* Accordion \/ expandable *\/\n.timeline {\n position: relative;\n padding-left: 32px;\n}\n.timeline::before {\n content: ''; position: absolute;\n left: 7px; top: 6px; bottom: 6px;\n width: 2px;\n background: linear-gradient(180deg, var(--indigo) 0%, var(--violet) 50%, var(--magenta) 100%);\n border-radius: 2px;\n}\n.timeline-item { position: relative; padding-bottom: 32px; }\n.timeline-item::before {\n content: ''; position: absolute;\n left: -32px; top: 6px;\n width: 16px; height: 16px;\n background: var(--white);\n border: 3px solid var(--indigo);\n border-radius: 50%;\n}\n.timeline-item:last-child { padding-bottom: 0; }\n.timeline-date {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n text-transform: uppercase;\n letter-spacing: .06em;\n margin-bottom: 6px;\n}\n.timeline-title { font-weight: 700; font-size: 1.15rem; color: var(--ink); margin-bottom: 6px; }\n.timeline-body { color: var(--ink-muted); font-size: 1rem; line-height: 1.6; }\n\n\/* Legal\/disclaimer microcopy *\/\n.fine { font-size: .88rem; color: var(--ink-muted); line-height: 1.6; }\n\n\/* ========== RESPONSIVE FINE-TUNING ========== *\/\n\n\/* Tablet tuning *\/\n@media (max-width: 1024px) {\n .hero { padding: clamp(4rem, 8vw, 6rem) 0 clamp(3rem, 6vw, 5rem); }\n}\n\n\/* Mobile tuning \u2014 < 640px *\/\n@media (max-width: 640px) {\n h1 { font-size: clamp(2.1rem, 9vw, 3rem); }\n h2 { font-size: clamp(1.65rem, 6.5vw, 2.2rem); }\n h3 { font-size: 1.25rem; }\n .lead { font-size: 1.08rem; }\n .hero { padding: 3.5rem 0 3rem; }\n .hero .lead { font-size: 1.08rem; }\n .section { padding: 3.5rem 0; }\n .section-sm { padding: 2.5rem 0; }\n .card, .pillar { padding: 24px; }\n .btn { padding: 14px 22px; font-size: .95rem; }\n .stat-value { font-size: clamp(2.2rem, 10vw, 2.8rem); }\n}\n\n\/* Small mobile \u2014 < 380px *\/\n@media (max-width: 380px) {\n body { font-size: 15px; }\n h1 { font-size: 2rem; }\n .wrap, .narrow { padding: 0 16px; }\n .hero { padding: 3rem 0 2.5rem; }\n}\n\n\/* Safety: horizontal overflow prevention *\/\nhtml, body { overflow-x: hidden; max-width: 100%; }\nimg, svg, video { max-width: 100%; height: auto; }\ntable { max-width: 100%; }\n\n<\/style>\n<\/head>\n<body>\n\n<header class=\"nav\">\n <div class=\"nav-inner\">\n <a class=\"nav-brand\" href=\"index.html\"><img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\"><\/a>\n <nav><ul class=\"nav-links\">\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"investors.html\" class=\"is-active\">Investors<\/a><\/li>\n <\/ul><\/nav>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n\n <div class=\"nav-mobile\">\n <ul>\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"investors.html\" class=\"is-active\">Investors<\/a><\/li>\n <\/ul>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n<\/header>\n\n\n<section class=\"hero\" style=\"padding:clamp(4rem,7vw,6rem) 0;\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Investors<\/span>\n <h1 style=\"margin-top:22px;\">A late-stage, first-in-class oral asset in a<br><em>$15B+ market.<\/em><\/h1>\n <p class=\"lead\" style=\"margin-top:22px;\">\n Azuriya Pharma is positioned to rapidly prove a novel oral IBD mechanism \u2014 leveraging\n ~400 patients of prior human safety, preclinical validation across acute and chronic\n colitis models, and composition of matter protection through 2044+.\n <\/p>\n <div style=\"margin-top:36px; display:flex; gap:14px; flex-wrap:wrap;\">\n <a href=\"contact.html#investors\" class=\"btn btn-emerald\">Request Investor Package \u2192<\/a>\n <a href=\"#financing\" class=\"btn btn-light\">Financing Scenarios<\/a>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <div style=\"max-width:720px;\">\n <span class=\"eyebrow\">Investment Thesis<\/span>\n <h2 class=\"mt-2\">Six reasons Azuriya is differentiated.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <\/div>\n\n <div class=\"pillars mt-4\">\n <article class=\"pillar\">\n <div class=\"pillar-num\">01 \u00b7 Market<\/div>\n <h3 class=\"pillar-title\">$15B+ market with sustained unmet need<\/h3>\n <p class=\"pillar-body\">More than half of 7M global IBD patients fail to reach durable remission. Attractive Phase 2\/3 M&A interest from global pharma.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">02 \u00b7 MOA<\/div>\n <h3 class=\"pillar-title\">Upstream \u00b7 combinable \u00b7 non-immunosuppressive<\/h3>\n <p class=\"pillar-body\">APE1\/Ref-1 sits upstream of NF-\u03baB, HIF-1\u03b1, STAT3, and AP-1 \u2014 designed to combine with every approved class without mechanistic redundancy.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">03 \u00b7 Safety<\/div>\n <h3 class=\"pillar-title\">~400 patients de-risk the program<\/h3>\n <p class=\"pillar-body\">Clean safety profile across liver, oncology, and diabetic retinopathy. No treatment-related SAEs; 600 mg\/day RP2D established.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">04 \u00b7 Preclinical<\/div>\n <h3 class=\"pillar-title\">Compelling efficacy across IBD models<\/h3>\n <p class=\"pillar-body\">Ref-1 compares favorably to approved\/emerging MOAs across acute DSS, chronic Winnie, adoptive transfer, and T-cell transfer.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">05 \u00b7 Patents<\/div>\n <h3 class=\"pillar-title\">Composition of matter through 2044+<\/h3>\n <p class=\"pillar-body\">7 patent families covering compound, methods, and formulation. Calcium-salt polymorph IP through 2044 before 5-year PTE.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">06 \u00b7 POC Plan<\/div>\n <h3 class=\"pillar-title\">Rapid Phase 2a in Australia<\/h3>\n <p class=\"pillar-body\">$1M USD POC leveraging AUS R&D incentives. 6-month FPI, 12-month topline data, then pivot to FDA-approvable Phase 2b.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Market Opportunity<\/span>\n <h2 class=\"mt-2\">A $15B+ market ready for new combinable oral MOAs.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"grid-2 mt-4\" style=\"align-items:center;\">\n <div class=\"stats\" style=\"grid-template-columns:1fr 1fr;\">\n <div class=\"stat\">\n <div class=\"stat-value\">7M<\/div>\n <div class=\"stat-label\">Global IBD Patients<\/div>\n <\/div>\n <div class=\"stat\">\n <div class=\"stat-value\">$15B+<\/div>\n <div class=\"stat-label\">Global Market Size<\/div>\n <\/div>\n <div class=\"stat\" style=\"border-bottom:0;\">\n <div class=\"stat-value\">8%<\/div>\n <div class=\"stat-label\">CAGR Through 2030<\/div>\n <\/div>\n <div class=\"stat\" style=\"border-bottom:0; border-right:0;\">\n <div class=\"stat-value\">50%+<\/div>\n <div class=\"stat-label\">Fail 1L Therapy<\/div>\n <\/div>\n <\/div>\n <div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.6rem; letter-spacing:-0.02em;\">US Population \u2014 Indication Breakdown<\/h3>\n <div class=\"mt-3\" style=\"background:var(--white); border:1px solid var(--line); border-radius:var(--r-md); overflow:hidden;\">\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px; border-bottom:1px solid var(--line);\">\n <span style=\"font-weight:600;\">IBD (total)<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">3+ million<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px; border-bottom:1px solid var(--line);\">\n <span>Ulcerative Colitis<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">1+ million<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px; border-bottom:1px solid var(--line);\">\n <span>Crohn's Disease<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">~1 million<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:space-between; padding:14px 18px;\">\n <span>Non-GI Implications<\/span>\n <span class=\"mono\" style=\"color:var(--indigo);\">~1 million<\/span>\n <\/div>\n <\/div>\n <p class=\"fine mt-2\">Sources: CDC; gastrojournal.org; PubMed 15168363.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Robust Pharma M&A in IBD<\/span>\n <h2 class=\"mt-2\">$25B+ invested by big pharma across recent IBD transactions.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n These transactions highlight strategic interest in new mechanisms beyond traditional\n TNF \/ IL-12\/23 inhibition \u2014 including TREM1, NLRX1, TL1A, S1P, and integrin targets. The\n appeal lies in both differentiated biology and combination potential with existing\n therapies, with an increasing focus on orals.\n <\/p>\n\n <div class=\"mt-4\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr>\n <th>Date<\/th>\n <th>Stage<\/th>\n <th>Deal ($M)<\/th>\n <th>Acquired<\/th>\n <th>Acquirer<\/th>\n <th>Indication<\/th>\n <th>Asset \/ MOA<\/th>\n <th>Admin<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Jun '24<\/td><td>Phase 1a<\/td><td><strong>$250<\/strong><\/td>\n <td>Celsius Therapeutics<\/td><td>AbbVie<\/td>\n <td>Healthy volunteers<\/td>\n <td>CEL383 anti-TREM1 mAb<\/td><td>IV<\/td>\n <\/tr>\n <tr>\n <td>May '24<\/td><td>Phase 2a<\/td><td><strong>$138<\/strong><\/td>\n <td>Landos Biopharma<\/td><td>AbbVie<\/td>\n <td>UC<\/td>\n <td>NX-13 NLRX1 agonist small molecule<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Jun '23<\/td><td>Phase 2a<\/td><td><strong>$350<\/strong><\/td>\n <td>Spyre Therapeutics<\/td><td>Series B<\/td>\n <td>UC, Crohn's<\/td>\n <td>Antibody platform anti-TL1A \/ IL-23 \/ \u03b14\u03b27<\/td><td>SC<\/td>\n <\/tr>\n <tr>\n <td>May '22<\/td><td>Phase 2a<\/td><td><strong>$1,100<\/strong><\/td>\n <td>Protagonist (PTG-200)<\/td><td>Johnson & Johnson<\/td>\n <td>IBD<\/td>\n <td>PN-235 IL-23R antagonist peptide<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Jul '24<\/td><td>Phase 2b<\/td><td><strong>$3,200<\/strong><\/td>\n <td>Morphic Therapeutic<\/td><td>Eli Lilly<\/td>\n <td>UC, Crohn's<\/td>\n <td>MORF-057 \u03b14\u03b27 inhibitor small molecule<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Dec '23<\/td><td>Phase 2b<\/td><td><strong>$7,100<\/strong><\/td>\n <td>Telavant (Roivant\/Pfizer)<\/td><td>Roche<\/td>\n <td>IBD<\/td>\n <td>RVT-3101 anti-TL1A mAb<\/td><td>SC<\/td>\n <\/tr>\n <tr>\n <td>Jun '23<\/td><td>Phase 2b<\/td><td><strong>$10,800<\/strong><\/td>\n <td>Prometheus Biosciences<\/td><td>Merck<\/td>\n <td>UC, Crohn's<\/td>\n <td>PRA023 anti-TL1A mAb<\/td><td>IV\/SC<\/td>\n <\/tr>\n <tr>\n <td>Apr '23<\/td><td>Phase 3<\/td><td><strong>$6,700<\/strong><\/td>\n <td>Arena Pharmaceuticals<\/td><td>Pfizer<\/td>\n <td>UC<\/td>\n <td>Etrasimod selective S1P modulator<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <tr>\n <td>Oct '23<\/td><td>Phase 3<\/td><td><strong>$750<\/strong><\/td>\n <td>Abivax<\/td><td>Follow-on<\/td>\n <td>UC<\/td>\n <td>Obefazimod miR-124 enhancer<\/td><td><span style=\"color:var(--emerald); font-weight:700;\">Oral<\/span><\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <p class=\"fine mt-3\">Big pharma has invested over $25 billion to capture the next wave of IBD innovation, with an increasing premium for differentiated oral assets.<\/p>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-lavender\" id=\"financing\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Financing Scenarios<\/span>\n <h2 class=\"mt-2\">A staged capital plan to NDA.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n Three capital rounds through NDA filing, each aligned to a value-creating clinical or\n regulatory milestone. Structures flex with investor interest and partnership dynamics.\n <\/p>\n\n <div class=\"grid-3 mt-4\">\n <article class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-indigo\">Round 1 \u00b7 2Q 2026<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">$8M \u2013 $20M+<\/h3>\n <p class=\"fine mt-2\">Common stock or convertible note. Funds 12\u201324 months of operations through IND transfer, CTN submission, and Phase 2a initiation.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.9rem;\">\n <li>Newco formation & IU licensing<\/li>\n <li>GMP Ca-salt drug substance \/ drug product<\/li>\n <li>Phase 2a site contracting & enrollment<\/li>\n <\/ul>\n <\/article>\n <article class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-violet\">Round 2 \u00b7 2027<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">$20M \u2013 $30M+<\/h3>\n <p class=\"fine mt-2\">Crossover, PIPE \/ reverse merger, or IPO round. Funds Phase 2b initiation alongside Phase 2a topline readout.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.9rem;\">\n <li>Phase 2a topline data<\/li>\n <li>Phase 2b protocol & site selection<\/li>\n <li>Strategic partnership discussions<\/li>\n <\/ul>\n <\/article>\n <article class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-new\">Round 3 \u00b7 2028<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">$50M \u2013 $100M+<\/h3>\n <p class=\"fine mt-2\">IPO round or regional partnership. Funds Phase 2b through to topline data and positions the asset for Phase 3 or strategic exit.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.9rem;\">\n <li>Nasdaq listing pathway<\/li>\n <li>Phase 2b topline + FDA end-of-P2<\/li>\n <li>Global commercial strategy<\/li>\n <\/ul>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Exit Strategy<\/span>\n <h2 class=\"mt-2\">Multiple paths to liquidity at inflection points.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n The IBD market presents multiple liquidity pathways, driven by sustained M&A\n activity, strategic partnerships, and strong public market interest in differentiated\n oral assets.\n <\/p>\n\n <div class=\"grid-3 mt-4\">\n <article class=\"card\">\n <span class=\"badge badge-new\">Path A<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">Strategic Acquisition<\/h3>\n <div style=\"margin:18px 0; padding:14px 18px; background:var(--cloud); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-size:.78rem; color:var(--ink-muted); text-transform:uppercase; letter-spacing:.1em;\">Target valuation<\/div>\n <div style=\"font-family:var(--f-display); font-size:1.8rem; font-weight:500; color:var(--indigo); letter-spacing:-0.02em;\">$500M \u2013 $1B+<\/div>\n <div class=\"fine mt-1\">Timeline: 24+ months<\/div>\n <\/div>\n <p class=\"fine\">Pharma acquires a differentiated oral asset with Phase 2 POC data \u2014 consistent with recent IBD transactions.<\/p>\n <\/article>\n\n <article class=\"card\">\n <span class=\"badge badge-violet\">Path B<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">Development Partner<\/h3>\n <div style=\"margin:18px 0; padding:14px 18px; background:var(--cloud); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-size:.78rem; color:var(--ink-muted); text-transform:uppercase; letter-spacing:.1em;\">Deal structure<\/div>\n <div style=\"font-family:var(--f-display); font-size:1.8rem; font-weight:500; color:var(--indigo); letter-spacing:-0.02em;\">$150M+ upfront<\/div>\n <div class=\"fine mt-1\">Timeline: 12+ months \u00b7 plus milestones & royalties<\/div>\n <\/div>\n <p class=\"fine\">Upfront + development\/commercial milestones + double-digit royalty structure. Preserves upside with strategic partner resources.<\/p>\n <\/article>\n\n <article class=\"card\">\n <span class=\"badge badge-indigo\">Path C<\/span>\n <h3 style=\"margin-top:12px; font-family:var(--f-display); font-weight:500; font-size:1.4rem;\">Public Listing (IPO)<\/h3>\n <div style=\"margin:18px 0; padding:14px 18px; background:var(--cloud); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-size:.78rem; color:var(--ink-muted); text-transform:uppercase; letter-spacing:.1em;\">Target market cap<\/div>\n <div style=\"font-family:var(--f-display); font-size:1.8rem; font-weight:500; color:var(--indigo); letter-spacing:-0.02em;\">$200M+<\/div>\n <div class=\"fine mt-1\">Timeline: 12 \u2013 24 months<\/div>\n <\/div>\n <p class=\"fine\">Nasdaq listing to independently fund Phase 3. Maintains company independence and full economics on a first-in-class platform.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Competitive Benchmarking<\/span>\n <h2 class=\"mt-2\">APX3330 vs. approved & emerging IBD MOAs.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n Unlike single-target approved therapies, APX3330 converges on multiple validated IBD nodes \u2014 orally, safely, and with no biosimilar risk.\n <\/p>\n\n <div class=\"mt-4\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr>\n <th>Attribute<\/th>\n <th style=\"background:var(--indigo); color:var(--white);\">APX3330<\/th>\n <th>Obefazimod (Abivax)<\/th>\n <th>Entyvio<\/th>\n <th>Rinvoq<\/th>\n <th>Skyrizi \/ Tremfya<\/th>\n <th>PRA023 \/ TL1A<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td><strong>Target<\/strong><\/td>\n <td><strong style=\"color:var(--indigo);\">Ref-1<\/strong><\/td>\n <td>miR-124 \/ TNF\u03b1<\/td>\n <td>\u03b14\u03b27<\/td>\n <td>JAK<\/td>\n <td>IL-23<\/td>\n <td>TL1A<\/td>\n <\/tr>\n <tr>\n <td><strong>Upstream MOA<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Gene transcription<\/td>\n <td>Post-transcriptional<\/td>\n <td>Immune modulation<\/td>\n <td>Signal transduction<\/td>\n <td>Cytokine suppression<\/td>\n <td>Immune modulation<\/td>\n <\/tr>\n <tr>\n <td><strong>Oral<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>Injectable<\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>Injectable<\/td>\n <td>Injectable<\/td>\n <\/tr>\n <tr>\n <td><strong>Neuroprotection<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td>\n <\/tr>\n <tr>\n <td><strong>Hematopoiesis Protection<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">\u2713 Yes<\/td>\n <td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td><td>No<\/td>\n <\/tr>\n <tr>\n <td><strong>Exclusivity Through<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">2043+<\/td>\n <td>2035<\/td>\n <td style=\"color:var(--ink-muted);\">2028<\/td>\n <td>2037<\/td>\n <td>2031 \u2013 2032<\/td>\n <td>2035<\/td>\n <\/tr>\n <tr>\n <td><strong>Safety Profile<\/strong><\/td>\n <td style=\"color:var(--emerald); font-weight:700;\">~400 patients \u00b7 clean<\/td>\n <td>Phase 3 positive<\/td>\n <td>Approved<\/td>\n <td style=\"color:var(--magenta);\">Black box<\/td>\n <td>Approved<\/td>\n <td>Phase 2\/3<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <p class=\"fine mt-3\">Data confirmation in process. See data room for complete competitive analysis.<\/p>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Operational & Financing Milestones<\/span>\n <h2 class=\"mt-2\">Path to value creation.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"timeline mt-4\">\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">1H 2026 \u00b7 Newco Launch<\/div>\n <div class=\"timeline-title\">Company formation & asset consolidation<\/div>\n <div class=\"timeline-body\">Secure APX IP from OPUS \u00b7 finalize IU licensing \u00b7 close open diligence items \u00b7 recruit KOLs \u00b7 first financing round ($8\u201320M).<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2H 2026 \u00b7 Trial Prep<\/div>\n <div class=\"timeline-title\">IND transfer & Australian CTN<\/div>\n <div class=\"timeline-body\">Transfer IND with FDA \u00b7 AUS subsidiary and CTN submission \u00b7 preclinical combination studies \u00b7 site selection and contracting \u00b7 GMP Ca-salt drug substance and drug product.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">1H 2027 \u00b7 Phase 2a + 2b Start<\/div>\n <div class=\"timeline-title\">Patient enrollment begins<\/div>\n <div class=\"timeline-body\">Open-label enrollment \u00b7 safety monitoring \u00b7 early open-label data \u00b7 any preclinical studies required for Phase 3 readiness.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2H 2027 \u00b7 Phase 2a Topline<\/div>\n <div class=\"timeline-title\">Proof of concept readout<\/div>\n <div class=\"timeline-body\">Primary and secondary endpoints \u00b7 safety data \u00b7 biomarker signals \u00b7 publications \u00b7 active strategic partnership discussions.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2028 \u00b7 Phase 2b Topline<\/div>\n <div class=\"timeline-title\">FDA-approvable endpoints readout<\/div>\n <div class=\"timeline-body\">Full Phase 2b efficacy and safety data \u00b7 publications \u00b7 End-of-Phase-2 meeting preparation \u00b7 position for strategic exit, Phase 3, or NDA planning.<\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-ink\" style=\"padding:clamp(4rem,8vw,6rem) 0;\">\n <div class=\"wrap text-center\" style=\"max-width:720px;\">\n <span class=\"eyebrow\" style=\"color:var(--emerald-bright);\">Investor Inquiries<\/span>\n <h2 style=\"margin-top:22px;\">Access the full investor package.<\/h2>\n <p class=\"lead\" style=\"color:rgba(255,255,255,.75); margin:22px auto 32px;\">\n Request the full deck, data room, and a conversation with the Azuriya leadership team.\n Confidential materials available under NDA.\n <\/p>\n <div style=\"display:flex; gap:14px; justify-content:center; flex-wrap:wrap;\">\n <a href=\"contact.html#investors\" class=\"btn btn-emerald\">Request Package \u2192<\/a>\n <a href=\"contact.html\" class=\"btn btn-light\">Schedule a Call<\/a>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section section-sm\">\n <div class=\"wrap\">\n <p class=\"fine\">\n <strong>Forward-Looking Statements.<\/strong> This page contains forward-looking statements\n regarding Azuriya Pharma's clinical development plans, financing strategy, and potential\n exit pathways, including expected timelines and valuations. Actual results and outcomes\n may differ materially from those contemplated. APX3330 is an investigational compound and\n has not been approved by the FDA, EMA, or any other regulatory authority. Past transactions\n and valuations cited are for reference only and do not guarantee similar outcomes.\n Nothing on this page constitutes an offer to sell or a solicitation to buy any security.\n <\/p>\n <\/div>\n<\/section>\n\n<footer class=\"foot\">\n <div class=\"wrap\">\n <div class=\"foot-grid\">\n <div class=\"foot-brand\">\n <img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\">\n <p style=\"max-width:340px; font-size:.95rem; line-height:1.6;\">A late-stage, first-in-class oral small-molecule therapy targeting root causes of Inflammatory Bowel Disease through upstream modulation.<\/p>\n <\/div>\n <div><h4>Science<\/h4><ul>\n <li><a href=\"science.html\">Mechanism of Action<\/a><\/li>\n <li><a href=\"science.html#pipeline\">Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Company<\/h4><ul>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"about.html#team\">Team<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Contact<\/h4><ul>\n <li><a href=\"contact.html\">General Inquiries<\/a><\/li>\n <li><a href=\"contact.html#partnership\">Partnerships<\/a><\/li>\n <li><a href=\"contact.html#investors\">Investor Relations<\/a><\/li>\n <\/ul><\/div>\n <\/div>\n <div class=\"foot-copy\">\n <span>\u00a9 2026 Azuriya Pharma. All rights reserved.<\/span>\n <span>APX3330 is an investigational compound and has not been approved by any regulatory authority.<\/span>\n <\/div>\n <\/div>\n<\/footer>\n\n\n<script>\n(function(){\n var nav = document.querySelector('.nav');\n var toggle = document.querySelector('.nav-toggle');\n if (!nav || !toggle) return;\n toggle.addEventListener('click', function(){ nav.classList.toggle('is-open'); });\n var mobileLinks = nav.querySelectorAll('.nav-mobile a');\n mobileLinks.forEach(function(a){\n a.addEventListener('click', function(){ nav.classList.remove('is-open'); });\n });\n})();\n<\/script>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Investors \u2014 Azuriya Pharma Home Science & Pipeline Publications About Investors Contact Home Science & Pipeline Publications About Investors Contact Investors A late-stage, first-in-class oral asset in a$15B+ market. Azuriya Pharma is positioned to rapidly prove a novel oral IBD mechanism \u2014 leveraging ~400 patients of prior human safety, preclinical validation across acute and chronic …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-12","page","type-page","status-publish","hentry","post","without-featured-image"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/12","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12"}],"version-history":[{"count":0,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/12\/revisions"}],"wp:attachment":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}